Friday, December 5, 2014 - London, UK - The Biogerontology Research Foundation (BGRF), a UK-based charity founded to support ageing research and address the challenges of a rapidly ageing population, will present new economic longevity research at the second Big Data Science in Medicine congress in Oxford on December 8.
The research, "Longevity expectations in the pension fund, insurance, and employee benefits industry", was recently published in the open-access journal Psychology Research and Behavior Management, and details an extensive survey of International Employee Benefits Association (IEBA) members.
Alex Zhavoronkov, Director of the BGRF and CEO of InSilico Medicine, commented: "The progress in Big Data Science in Medicine is comparable only to the Internet revolution with thousands of new entrants joining the field every year. We are pleased to present our research at the first and leading continuous conference series at the University of Oxford organized by a group of dedicated professionals bringing together the industry's top thought leaders."
Avi Roy, Founder of the Big Data Science in Medicine conferences, commented: "At the Big Data Science in Medicine conference, we envision how big-data can help us gain key insights into the biological process of aging, and accelerate personalised medicine to bring health and longevity to all. Dr. Zhavoronkov's research highlights the issues with the available therapies for age-related disorders, and paves the way to change the future of medicine."
The event will take place from 4pm to 10pm in the Saïd Business School, University of Oxford, and will bring together luminaries from big data, biomedical science, artificial intelligence and regenerative medicine. The event is free to attend, but places are limited. Those interested should register at the link below to ensure their place is secured:
Notes to Editors
About the Biogerontology Research Foundation
The Biogerontology Research Foundation (a registered charity in England and Wales; registration number 1124054) seeks to fill a gap within the research community, whereby the current scientific understanding of the ageing process is not yet being sufficiently exploited to produce effective medical interventions. The BGRF will fund research which, building on the body of knowledge about how ageing happens, will develop biotechnological interventions to remediate the molecular and cellular deficits which accumulate with age and which underlie the ill-health of old age.
Addressing ageing damage at this most fundamental level will provide an important opportunity to produce the effective, lasting treatments for the diseases and disabilities of ageing, which are required to improve quality of life in the elderly. The BGRF seeks to use the entire scope of modern biotechnology to attack the changes that take place in the course of ageing, and to address not just the symptoms of age-related diseases but also the mechanisms of those diseases.